Charles Ricordel, MD, PhD, Thoracic Oncologist at CHU de Rennes. In this audio, he speaks about the ASCO 2022 Abstract Abstract 9039: Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with NSQ NSCLC expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
Summary:
The study duration for an individual patient will begin with the signing of the informed consent and will include a screening period of up to 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days after the last administration of study drug, and at least one follow-up visit after the end-of-treatment visit. Additional follow-up visits may be required until the adverse occurrences are resolved or stabilized (at least 30 days). Treatment may be continued until toxicity, progression, or the patient’s wish prevents it. If the patient discontinues study treatment for any reason other than disease progression, a 3-month follow-up visit will be scheduled until disease progression, the commencement of another anti-tumor medication, or death, whichever occurs first.